Welcome to our dedicated page for Angle Plc news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on Angle Plc stock.
Angle Plc (ANPCY) provides cutting-edge liquid biopsy solutions for cancer diagnostics and research. This news hub delivers official updates on clinical trial progress, regulatory milestones, and strategic partnerships shaping precision oncology.
Access verified announcements about the Parsortix system deployments, novel assay developments, and collaborations with pharmaceutical leaders. Investors and researchers will find timely reports on FDA submissions, peer-reviewed study publications, and innovations in circulating tumor cell (CTC) analysis.
Key updates include product launch details, intellectual property expansions, and clinical service offerings supporting drug development. All content undergoes strict verification to ensure accuracy in reporting financial and operational developments.
Bookmark this page for consolidated access to Angle Plc's latest advancements in non-invasive cancer diagnostics and genomic analysis technologies.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced the publication of research investigating a panel of prostate cancer gene transcripts in circulating tumor cells (CTCs). The study, conducted by the Medical University of Vienna, used ANGLE's Parsortix system to isolate CTCs from 38 prostate cancer patients. Key findings include:
1. 67% of localized prostate cancer patients were positive for CTC biomarker(s) at baseline.
2. 77% were positive for CTC biomarker(s) after treatment.
3. Strong correlation between specific CTC biomarkers and clinical parameters like tumor grade and stage.
The research supports ANGLE's pharma services business, demonstrating how Parsortix-enriched, CTC-based multi-marker analysis can enhance targeted therapy development and improve patient stratification in clinical trials. This approach could lead to new drug classes requiring a Parsortix-based companion diagnostic for regulatory clearance.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces the 100th peer-reviewed journal article using its Parsortix® system for circulating tumour cell (CTC) analysis. The latest publication, from researchers at Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano, reports on using the Parsortix system to isolate CTCs from triple negative breast cancer patients for whole genomic sequencing (WGS).
The study used machine learning to identify cancer genes associated with DNA proliferation and repair. The authors conclude that this cost-effective sequencing assay has potential to guide clinical patient management. The 100 publications span a decade of research across 24 cancer types, involving 42 independent institutions in 15 countries.
ANGLE's Chief Scientific Officer, Karen Miller, highlighted that CTC analysis has evolved from simple enumeration to detailed biomarker analysis using advanced techniques. She emphasized the potential of multi-analyte assessment in liquid biopsy as a less invasive and more cost-effective alternative to tissue biopsy.
ANGLE plc, a liquid biopsy company, announced interim results for H1 2024. Key highlights include:
- Revenues of £1.0 million (H1 2023: £1.2 million)
- Loss reduced by 21% to £7.7 million
- Cash position of £17.9 million as of June 30, 2024
- Three large pharma contracts secured with Eisai and AstraZeneca
- Strategic focus on pharma services implemented
- Cost savings of ~£8 million expected by end of 2024
- Fundraise of £9.3 million completed in June 2024
The company is prioritizing its large pharma strategy, aiming for cashflow positive trading in H2 2026. Full year 2024 revenue is expected between £3.0-£3.7 million, lower than previously anticipated due to headwinds in product sales.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with NuProbe USA, Inc. for the use of their proprietary pan-cancer next generation sequencing (NGS) panel. The agreement grants ANGLE an option for an exclusive global license to the NGS panel outside of China for analyzing circulating tumor cells (CTCs) and dual analysis of CTCs and circulating tumor DNA (ctDNA).
The NGS panel enables highly sensitive detection of over 6,500 DNA mutations in 61 clinically relevant genes. It has been validated on the Illumina sequencer and aligns with key drug targets under development by large pharma. This agreement aims to accelerate ANGLE's commercialization of its first pan-cancer molecular sequencing assay, with immediate applicability to pharma services customers and translational researchers using the Parsortix® system.
A pilot study conducted by ANGLE demonstrated that more mutations were identified exclusively in CTCs compared to ctDNA alone in breast, lung, and ovarian cancer patients, highlighting the potential value of profiling CTCs in addition to ctDNA.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced the release of its interim results for the six months ended 30 June 2024. The results will be published on Thursday 26 September 2024.
An analyst meeting is scheduled for 11:00 am BST on the same day at Berenberg's offices in London. A live webcast of the meeting will be accessible through ANGLE's Investor Centre page, with Q&A participation reserved for analysts. The webcast recording will be made available on ANGLE's website following the event.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has announced the publication of a clinical study supporting the FDA approval of its Parsortix PC1 system for isolating circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The study, published in the Journal of Experimental & Clinical Cancer Research, demonstrated the system's ability to capture and harvest CTCs from MBC patient blood samples for downstream analysis.
Key findings include:
- CTCs were identified in 45% of MBC patients
- CTC clusters were found in 56% of CTC-positive patients
- 70% of detected CTCs did not express the epithelial marker EpCAM
This data supported ANGLE's successful FDA De Novo request for the Parsortix PC1 system's classification as a Class II medical device in 2022.
ANGLE plc (ANPCY) has announced a major shareholding notification. Global Frontier Investments, , acting as General Partner and Investment Advisor to Global Frontier Partners, LP, has increased its stake in ANGLE plc to 6.85% of voting rights, up from 6.47% previously. This change occurred on 11 June 2024 and was notified to the issuer on 17 July 2024. The total number of voting rights held by Global Frontier Partners, LP is now 22,088,946 ordinary shares. This notification is in compliance with the standard form for notification of major holdings as required by regulatory authorities.
On July 12, 2024, Angle PLC, a UK-based company, announced a significant change in its major shareholdings. Dermot Keane, based in London, UK, has crossed the 5% threshold, increasing his voting rights from 4.90% to 8.09%, amounting to 26,110,422 voting rights. The notification was triggered by an acquisition of voting rights, with the official threshold crossing occurring on June 5, 2024. This information was published through the London Stock Exchange's Regulatory News Service (RNS), approved by the Financial Conduct Authority (FCA). No other financial instruments or changes in voting rights breakdown were reported.
Angle PLC, a leading liquid biopsy company, announced that all resolutions were passed at its Annual General Meeting held on July 11, 2024. This development confirms shareholder support for the company's strategic direction and operational plans. The resolutions covered various governance and corporate matters, underscoring the company’s commitment to advancing its liquid biopsy technologies.
For more information, stakeholders can contact Angle PLC at +44 (0) 1483 343434 or Berenberg, the company's NOMAD and Broker, at +44 (0) 20 3207 7800.
